Public Employees Retirement System of Ohio reduced its stake in shares of Fortrea Holdings Inc. (NASDAQ:FTRE – Free Report) by 78.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,083 shares of the company’s stock after selling 22,778 shares during the period. Public Employees Retirement System of Ohio’s holdings in Fortrea were worth $30,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. GAMMA Investing LLC lifted its stake in shares of Fortrea by 736.6% during the first quarter. GAMMA Investing LLC now owns 7,847 shares of the company’s stock worth $59,000 after buying an additional 6,909 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of Fortrea by 56.6% during the first quarter. Allspring Global Investments Holdings LLC now owns 17,343 shares of the company’s stock worth $122,000 after buying an additional 6,270 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Fortrea during the first quarter worth $575,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Fortrea during the first quarter worth $119,000. Finally, AQR Capital Management LLC lifted its stake in shares of Fortrea by 181.9% during the first quarter. AQR Capital Management LLC now owns 1,095,282 shares of the company’s stock worth $8,269,000 after buying an additional 706,779 shares during the period.
Insider Transactions at Fortrea
In related news, Director Peter M. Neupert bought 32,500 shares of the business’s stock in a transaction dated Monday, August 11th. The stock was acquired at an average price of $6.26 per share, with a total value of $203,450.00. Following the completion of the purchase, the director directly owned 98,132 shares of the company’s stock, valued at approximately $614,306.32. This trade represents a 49.52% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Erin L. Russell bought 9,854 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The shares were bought at an average cost of $10.15 per share, with a total value of $100,018.10. Following the purchase, the director directly owned 9,854 shares of the company’s stock, valued at approximately $100,018.10. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 72,354 shares of company stock valued at $507,168 and sold 10,311 shares valued at $94,635. Corporate insiders own 0.38% of the company’s stock.
Wall Street Analyst Weigh In
Read Our Latest Report on FTRE
Fortrea Stock Up 8.8%
FTRE stock opened at $10.13 on Thursday. The stock has a market capitalization of $919.80 million, a P/E ratio of -0.89 and a beta of 1.81. The firm has a 50-day simple moving average of $8.87 and a 200-day simple moving average of $6.71. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 1.87. Fortrea Holdings Inc. has a 52 week low of $3.97 and a 52 week high of $25.28.
Fortrea (NASDAQ:FTRE – Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.13. The business had revenue of $710.30 million during the quarter, compared to analysts’ expectations of $631.61 million. Fortrea had a negative net margin of 37.57% and a positive return on equity of 5.25%. Equities analysts forecast that Fortrea Holdings Inc. will post 0.51 earnings per share for the current fiscal year.
Fortrea Profile
Fortrea Holdings Inc, a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.
Read More
- Five stocks we like better than Fortrea
- 3 Warren Buffett Stocks to Buy Now
- Lowe’s vs. Home Depot: Which Benefits More From Lower Rates?
- What Are Dividend Achievers? An Introduction
- These 5 Beaten-Down Tech Stocks Could Catch Fire Next
- What is Insider Trading? What You Can Learn from Insider Trading
- Falcon Flex Drives Growth as CrowdStrike Bets on AI Security
Want to see what other hedge funds are holding FTRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fortrea Holdings Inc. (NASDAQ:FTRE – Free Report).
Receive News & Ratings for Fortrea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortrea and related companies with MarketBeat.com's FREE daily email newsletter.